findmyKOL
Clinical trialNCT02085304TerminatedPhase 1/PHASE2Interventional

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

SponsorSt. Joseph's Hospital and Medical Center, PhoenixEnrollment8Glioblastoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control. Recent studies show that survival improves for patients who get aggressive surgery to remove a tumor before starting radiation (RT) and chemotherapy (chemo) treatment. Surgery, RT and chemo are part of regular cancer care for GBM. RT is usually done in daily doses 5 days a week over about 6 weeks. Beams of radiation are aimed at the tumor site plus some of the normal brain tissue around the tumor area. GammaKnife® (GK) radiosurgery also delivers radiation but in a larger dose over one day. GK sends beams to a precise target (tumor location) and very little normal brain tissue that is nearby. This study will compare GK treatment to the usual RT treatment after surgery, and with chemo. We want to know: * How well each treatment keeps the tumor from growing back. * What the effects (good and bad) of the treatments are. * How you rate your quality of life. * How the treatment affects your ability to think, understand, reason, and remember. * How you rate your ability to think, understand, reason, and remember. * If using a certain type of MRI scan can show the difference between new tumor growth and changes caused by treatment. * If certain features found in tumor cells can help doctors predict how tumors will respond to treatment.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Kris A Smith, MD

    Barrow Neurological Institute at St. Joseph's Hospital and Medical Center

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Barrow Neurological Institute at St. Joseph'S Hospital and Medical Center

    Phoenix, Arizona, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 May 2013
Primary completion
30 May 2015
Completion
29 May 2018
Last update posted
19 Apr 2024
Registered enrollment
8
Registry id
NCT02085304

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.